Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics 2024年第一季度每股收益爲0.04美元（0.04美元），直列式，銷售額爲14.44億美元，超過13.59萬美元的預期
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $1.444 million which beat the analyst consensus estimate of $1.359 million by 6.22 percent. This is a 39.48 percent decrease over sales of $2.386 million the same period last year.
Lineage Cell Therapeutics（美國證券交易所股票代碼：LCTX）公佈的季度虧損爲每股0.04美元，符合分析師的共識預期。與去年同期每股虧損0.03美元（0.03）相比，下降了33.33％。該公司公佈的季度銷售額爲14.44億美元，比分析師普遍預期的13.59萬美元高出6.22％。這比去年同期的238.6萬美元的銷售額下降了39.48％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。